Gastroparesis is a rare but potentially debilitating side effect of GLP-1 agonists. Here’s how to recognize and prevent it.
Gastroparesis, defined by an **abnormal slowing of gastric emptying** without mechanical obstruction, has garnered considerable media attention with the advent of GLP-1 treatments. Although rare, this complication can be debilitating and may necessitate treatment discontinuation. Let’s review the current data.
Mechanism: Why do GLP-1s slow down the stomach?
The slowing of gastric emptying is an **intended pharmacological effect** of GLP-1 agonists, contributing to satiety and post-prandial glycemic regulation. GLP-1 reduces gastric antral contractions, relaxes the fundus, and increases pyloric tone. With tirzepatide, gastric emptying is slowed by **30 to 40%** at the start of treatment.
In the majority of patients, this slowing is moderate and tolerable. Gastroparesis occurs when this mechanism is excessive, leading to pathological gastric stasis with debilitating symptoms.
Epidemiology: How frequent is it?
Cases of severe gastroparesis under GLP-1 agonists are **rare**. The FDA analyzed pharmacovigilance databases (FAERS) and clinical studies: the estimated incidence is less than **1 per 1000 patient-years**. However, a significant slowing of gastric emptying (without reaching the threshold for gastroparesis) is much more frequent and manifests as the well-documented nausea and vomiting.
Symptoms of Gastroparesis
- Extreme early satiety: feeling full after a few bites
- Persistent nausea: not limited to the first few days post-injection, present daily
- Vomiting of undigested food: recognizable food several hours after the meal
- Severe abdominal bloating: palpable gastric distension
- Aggravated gastroesophageal reflux
- Excessive weight loss: beyond what is expected with treatment
- Post-prandial epigastric pain
Risk Factors
- Long-standing diabetes: diabetic autonomic neuropathy predisposes to gastroparesis
- Untreated hypothyroidism
- History of gastric surgery
- Concomitant use of medications that slow transit: opioids, anticholinergics
- High initial doses: this is why progressive titration is essential
Management
If gastroparesis is suspected, the first step is the **reduction or discontinuation of tirzepatide**. Symptoms generally improve within 1 to 4 weeks after cessation, confirming the drug-induced nature of the problem. Diagnosis is confirmed by a gastric emptying scintigraphy.
- Dose reduction or extended injection intervals
- Fractionated diet of 6-8 small daily meals, low in fat and fiber
- Metoclopramide (Primperan): prokinetic that accelerates gastric emptying
- Low-dose erythromycin: motilin agonist, used off-label
- Definitive discontinuation of tirzepatide if symptoms are severe or persistent
Implications for Anesthesia
An important practical point: patients on GLP-1 agonists have an increased risk of **residual gastric content** during general anesthesia. Current recommendations from the ASA (American Society of Anesthesiologists) suggest discontinuing weekly GLP-1 agonists at least **7 days before a scheduled procedure** requiring general anesthesia, or performing a pre-operative gastric ultrasound.
Track your symptoms and progress with the MounjaGO app.
FAQ
Is gastroparesis under Mounjaro reversible?
Yes, in the vast majority of cases. Symptoms disappear within 1 to 4 weeks after stopping or reducing tirzepatide. Cases of persistent gastroparesis after discontinuation are exceptional.
Should I stop Mounjaro before surgery?
Current recommendations suggest stopping tirzepatide 7 days before scheduled general anesthesia. Discuss this with your surgeon and anesthesiologist.
Do probiotics help with gastroparesis?
There is no solid evidence that probiotics treat gastroparesis. However, they may help manage associated gastrointestinal symptoms like bloating.